Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a leading pharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has approved an additional market approval filing for its drug candidate crisugabalin (HSK16149). This latest approval expands the drug’s indication to include the treatment of post-herpetic neuralgia (PHN). Crisugabalin, a Category 1 oral drug developed by Haisco, is a gamma-aminobutyric acid (GABA) analogue that is now approved for use in treating diabetic peripheral neuropathic pain (DPNP) in addition to PHN.
Crisugabalin received its initial approval in China for the treatment of adult DPNP in May of this year, marking a significant milestone for Haisco as it continues to expand the drug’s therapeutic applications.- Flcube.com
